Item


Fatty acid synthase expression in triple-negative breast cancer: a cross-sectional study

Triple-­‐negative breast cancer (TNBC) is a heterogeneous breast cancer subgroup with lacking of tumor markers, which lead to limitations in its treatment options and a consequent adverse prognosis. For this, the absence of effective targeted therapies requires new biomarkers to develop therapeutic strategies in the futureFatty acid synthase (FASN), which is overexpressed in several human carcinomas including triple-­‐negative cell lines, could be a potential novel biomarker and a therapeutic target or co-­‐target in TNBC. Main objective: To characterize FASN expression levels in TNBC patient tissue samples, compared to FASN expression levelsin non-­‐tumoral breast tissue samples, obtained between 1990 and 2012 from oncologic patients of Institut Català d’Oncologia (ICO) in Hospital Universitari de GironaDr. Josep TruetaDesign: Cross-­‐sectional study conducted between January 2014 and December 2014Methods: One hundred and four TNBC tissue samples have been analysed and gradedaccording to FASN expression levels by immunohistochemistry methods, and subsequently classified in two categories: low (0+/1+) and high (2+/3+) expression ofFASN. In parallel, clinical records from 90 TNBC patients have been collected, and clinical and histopathological characteristics of these patients have been described besides evaluating its association with the corresponding FASN expression results

Facultat de Medicina

Manager: Viñas, Gemma
Puig, Teresa
Other contributions: Universitat de Girona. Facultat de Medicina
Author: Roqué Lloveras, Ariadna
Abstract: Triple-­‐negative breast cancer (TNBC) is a heterogeneous breast cancer subgroup with lacking of tumor markers, which lead to limitations in its treatment options and a consequent adverse prognosis. For this, the absence of effective targeted therapies requires new biomarkers to develop therapeutic strategies in the futureFatty acid synthase (FASN), which is overexpressed in several human carcinomas including triple-­‐negative cell lines, could be a potential novel biomarker and a therapeutic target or co-­‐target in TNBC. Main objective: To characterize FASN expression levels in TNBC patient tissue samples, compared to FASN expression levelsin non-­‐tumoral breast tissue samples, obtained between 1990 and 2012 from oncologic patients of Institut Català d’Oncologia (ICO) in Hospital Universitari de GironaDr. Josep TruetaDesign: Cross-­‐sectional study conducted between January 2014 and December 2014Methods: One hundred and four TNBC tissue samples have been analysed and gradedaccording to FASN expression levels by immunohistochemistry methods, and subsequently classified in two categories: low (0+/1+) and high (2+/3+) expression ofFASN. In parallel, clinical records from 90 TNBC patients have been collected, and clinical and histopathological characteristics of these patients have been described besides evaluating its association with the corresponding FASN expression results
Document access: http://hdl.handle.net/2072/254639
Language: eng
Publisher: Facultat de Medicina
Rights: Attribution-NonCommercial-NoDerivs 3.0 Spain
Rights URI: http://creativecommons.org/licenses/by-nc-nd/3.0/es/
Subject: Breast cancer
Mama -- Càncer
Title: Fatty acid synthase expression in triple-negative breast cancer: a cross-sectional study
Type: info:eu-repo/semantics/bachelorThesis
Repository: Recercat

Subjects

Authors